| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| afm13 | immunoglobulin gamma fc receptor iiia | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] Mycosis Fungoides[MeSHID:D009182] Peripheral T-Cell Lymphoma[MeSHID:D016411] Hodgkin Disease[MeSHID:D006689] |
NA | phase 2 | antibody |
| afm13 | lymphocyte activation antigen cd30 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] Mycosis Fungoides[MeSHID:D009182] Peripheral T-Cell Lymphoma[MeSHID:D016411] Hodgkin Disease[MeSHID:D006689] |
NA | phase 2 | unknown |
| afm13 | lymphocyte activation antigen cd30 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma[MeSHID:D008223] Mycosis Fungoides[MeSHID:D009182] Peripheral T-Cell Lymphoma[MeSHID:D016411] Hodgkin Disease[MeSHID:D006689] |
NA | phase 2 | antibody |
| click here to return to the previous page | ||||||||